Jukka Westerbacka

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Insulin glargine 300 U/mL safety data in pregnancy.

Insulin glargine 300 U/mL safety data in pregnancy.

Journal: Diabetes, obesity & metabolism

Published: November 20, 2024

Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head-to-head randomized controlled InRange trial.

Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head-to-head randomized controlled InRange trial.

Journal: Diabetes, obesity & metabolism

Published: August 23, 2022

Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in people with type 2 diabetes: The DELIVER-G study.

Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in people with type 2 diabetes: The DELIVER-G study.

Journal: Diabetes, obesity & metabolism

Published: January 27, 2022

A review of reusable insulin pens and features of TouStar-a new reusable pen with a dedicated cartridge.

A review of reusable insulin pens and features of TouStar-a new reusable pen with a dedicated cartridge.

Journal: Diabetology & metabolic syndrome

Published: August 27, 2021

Clinical outcomes in high-hypoglycaemia-risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first-generation basal insulin analogue in the United States : Results from the DELIVER High Risk real-world study.

Clinical outcomes in high-hypoglycaemia-risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first-generation basal insulin analogue in the United States : Results from the DELIVER High Risk real-world study.

Journal: Endocrinology, diabetes & metabolism

Published: August 20, 2021

Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial.

Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial.

Journal: Diabetes, obesity & metabolism

Published: October 27, 2020

How many people with type 2 diabetes fulfil the eligibility criteria for randomized, controlled trials of insulin glargine 300 U/mL in a real-world setting?

How many people with type 2 diabetes fulfil the eligibility criteria for randomized, controlled trials of insulin glargine 300 U/mL in a real-world setting?

Journal: Diabetes, obesity & metabolism

Published: July 01, 2020

Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus.

Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus.

Journal: Current medical research and opinion

Published: December 24, 2019

Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial.

Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial.

Journal: Diabetes, obesity & metabolism

Published: December 18, 2019

Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study.

Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study.

Journal: Diabetes, obesity & metabolism

Published: July 15, 2019

Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real-world study.

Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real-world study.

Journal: Diabetes, obesity & metabolism

Published: March 26, 2019

Switching to insulin glargine 300 units/mL in real-world older patients with type 2 diabetes (DELIVER 3).

Switching to insulin glargine 300 units/mL in real-world older patients with type 2 diabetes (DELIVER 3).

Journal: Diabetes, obesity & metabolism

Published: March 18, 2019

Showing 1-12 of 19

Last Updated: 09/26/2026